“Vancomycin’s safety and tolerability issues, requisite renal dosing and drug-level monitoring, and reduced susceptibility to MRSA are key areas upon which current and emerging therapies can differentiate themselves and capitalize on physicians turning away from vancomycin IV – a trend that we expect will continue in the near future,” said Associate Therapeutic Class Director of Infectious Diseases Brenda Perez-Cheeks, Ph.D.
While the availability of several products for the treatment of MRSA infections has dampened the call for new therapies in this space, the majority of surveyed physicians feel that there is room in the market for new therapies. Niche and untapped opportunities in the MRSA market still exist for therapies with proven efficacy in difficult-to-treat infections, for new therapies with notable improvements over current treatment options, and for those that are suitable for outpatient management of MRSA infections. Indeed two key developing anti-MRSA agents, Durata’s dalbavancin and Trius/Bayer’s tedizolid, are poised to be challengers to currently-available MRSA agents. Over 80 percent of physicians believe that dalbavancin is most appropriate for the outpatient setting, which is consistent with dalbavancin’s once-weekly dosing, and tedizolid, a second generation oxazolidinone, has potential improvements in safety during protracted use over its predecessor linezolid.
Regarding anticipated use of Forest/AstraZeneca/Dainippon Sumitomo’s Teflaro/Zinforo (ceftaroline), at least one-third of physicians in this study plan to prescribe ceftaroline and find use for the drug in the treatment of EMA-approved indications and for nosocomial pneumonia, diabetic foot infections, and community-acquired pneumonia due to MRSA.